RT Journal Article
SR Electronic
T1 Serious infections with antirheumatic therapy: are biologicals worse?
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP iii54
OP iii57
DO 10.1136/ard.2006.058503
VO 65
IS suppl 3
A1 K L Winthrop
YR 2006
UL http://ard.bmj.com/content/65/suppl_3/iii54.abstract
AB This paper reviews the current evidence for the role of antirheumatic therapy in the development of serious infections in patients with rheumatoid arthritis (RA). Prednisone is clearly associated with increased infectious risk, but no definitive data link methotrexate to infection. Emerging data suggest that biological agents also pose increase infectious risk, particularly when used in combination with corticosteroids or methotrexate. Further research is needed in this important aspect of RA treatment. In the meantime, the author recommends that physicians should remain vigilant for serious infections in their patients with RA and use appropriate vaccines and screening procedures to mitigate their risk.